checkAd

     150  0 Kommentare Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S. - Seite 2

    Avoid co-administration of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; however, if this is unavoidable, closely monitor the absolute neutrophil count. Avoid co-administration with UGT1A6 inhibitors. Allow at least a 4-hour interval between administration of deferiprone and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc).

    The most common adverse reactions are (incidence ≥5%) nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia, and neutropenia.

    Inform patients that their urine might show a reddish/brown discoloration due to the excretion of iron. This is a very common sign of the desired effect, and it is not harmful.

    Please see full Prescribing Information, including boxed WARNING and Medication Guide.

    ¹ Source: https://rarediseases.org/rare-diseases/thalassemia-major/#:~:text=Beta ...

    About Taro

    Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

    Safe Harbor Statement

    Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements that do not describe historical facts or that refer or relate to events or circumstances the Company “estimates,” “believes,” or “expects” to happen or similar language, and statements. Although the Company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained. Forward-looking statements are applicable only as of the date on which they are made.

    Seite 2 von 2



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S. - Seite 2 Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or “the Company”) today announced the launch of a new specialty generic, deferiprone, an iron chelator indicated for the treatment of patients with transfusional iron overload due to …